Business
Avantor supplies laboratory, bioprocessing, chemicals, materials, consumables, and services to biopharma, healthcare, education, industrial, and technology customers.
Avantor revenue fell and swung to a large loss, while free cash flow declined despite lower debt and sizable insider buying.
The read at a glance✓ Audited against SEC data
- Business mix — Lab solutions and bioprocessingNote
- Revenue — Revenue fell 3.4%Watch
- Profit — Net loss was $530.2MWatch
- Cash — FCF fell 28.5%Watch
- Debt — Debt fell 2.7%OK
- Insiders — 8 buys / 1 sell; $9.9M boughtOK
- Accounting — Altman-Z distress; EQ safeWatch
Where the revenue comes from
Fiscal 2025, as Avantor, Inc. reports it. History and quarterly detail are in the app.
- Laboratory Solutions$4.4B
- Bioscience Production$2.2B
Leadership changes
From Avantor, Inc.'s own filings, the day they're filed.
- Jonathan Peacock · member · departureeff. 2025-10-10
- Gregory Lucier · director · appointmenteff. 2025-10-01
- Michael Stubblefield · Chief Executive Officer · departureeff. 2025-08-18
Latest filings
- 10-Q · Quarterly report2026-07-29
- 8-K · Company announcement2026-07-29
- 8-K · Company announcement2026-07-17
- 8-K · Company announcement2026-05-12
- 10-Q · Quarterly report2026-04-29
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Avantor, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.